Technical Analysis for EXAS - Exact Sciences Corporation
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Down | Flat |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Bearish Engulfing | Bearish | 0.00% | |
Fell Below 50 DMA | Bearish | 0.00% | |
MACD Bearish Signal Line Cross | Bearish | 0.00% | |
180 Bearish Setup | Bearish Swing Setup | 0.00% | |
Bollinger Band Squeeze | Range Contraction | 0.00% | |
BB Squeeze Started | Range Contraction | 0.00% | |
Crossed Above 20 DMA | Bullish | -3.43% | |
Crossed Above 50 DMA | Bullish | -3.43% | |
MACD Bullish Signal Line Cross | Bullish | -3.43% | |
Gapped Up | Strength | -3.43% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time |
---|---|
Fell Below 50 DMA | about 11 hours ago |
Down 2 % | about 11 hours ago |
50 DMA Support | about 11 hours ago |
60 Minute Opening Range Breakdown | about 12 hours ago |
Rose Above Previous Day's High | about 14 hours ago |
Get a Trading Assistant
- Earnings date: 04/24/2023
Exact Sciences Corporation Description
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing diagnostic screening products for the early detection and prevention of colorectal pre-cancer and cancer. The company develops the Cologuard, a non-invasive stool-based DNA colorectal cancer screening test that is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer. Its Cologuard test includes proprietary and patented methods that isolate and analyze the human DNA that are shed into stool every day from the exfoliation of cells that line the colon; and also protein marker to detect blood in the stool, utilizing an antibody-based fecal immunochemical test. The company's stool-based DNA colorectal cancer screening technology also focuses on the inflammatory bowel disease. It has collaboration, license, and purchase agreement with Genzyme Corporation, as well as with Mayo Clinic for developing tests to detect other gastro-intestinal cancers, primarily esophageal and pancreatic cancer. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.
Classification
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Medicine Cancer Medical Test Pancreatic Cancer Lab Testing Colorectal Cancer Inflammatory Bowel Disease Molecular Diagnostics Polyp Cancer Screening Genzyme Mayo Clinic Diagnostic Gastroenterology
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 76.94 |
52 Week Low | 29.285 |
Average Volume | 2,446,826 |
200-Day Moving Average | 47.39 |
50-Day Moving Average | 65.36 |
20-Day Moving Average | 63.90 |
10-Day Moving Average | 64.27 |
Average True Range | 2.95 |
RSI | 50.00 |
ADX | 21.03 |
+DI | 27.97 |
-DI | 16.22 |
Chandelier Exit (Long, 3 ATRs) | 60.62 |
Chandelier Exit (Short, 3 ATRs) | 68.37 |
Upper Bollinger Bands | 68.02 |
Lower Bollinger Band | 59.78 |
Percent B (%b) | 0.53 |
BandWidth | 12.90 |
MACD Line | 0.29 |
MACD Signal Line | 0.30 |
MACD Histogram | -0.0123 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 68.40 | ||||
Resistance 3 (R3) | 68.86 | 67.90 | 67.70 | ||
Resistance 2 (R2) | 67.90 | 66.83 | 67.68 | 67.46 | |
Resistance 1 (R1) | 66.04 | 66.16 | 65.56 | 65.58 | 67.22 |
Pivot Point | 65.08 | 65.08 | 64.85 | 64.86 | 65.08 |
Support 1 (S1) | 63.22 | 64.01 | 62.74 | 62.76 | 61.12 |
Support 2 (S2) | 62.26 | 63.34 | 62.04 | 60.88 | |
Support 3 (S3) | 60.40 | 62.26 | 60.65 | ||
Support 4 (S4) | 59.94 |